Role of platinum agents in the management of advanced pancreatic cancer
- 24 October 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 8 (16), 2719-2727
- https://doi.org/10.1517/14656566.8.16.2719
Abstract
Pancreatic cancer, one of the most common gastrointestinal tumors, has a 5-year survival rate of < 5%. Since 1997, when gemcitabine showed superior clinical benefit to single-agent 5-fluorouracil, it has remained the only standard chemotherapy approved by the US FDA for the treatment of advanced pancreatic cancer. Numerous new agents, both cytotoxic and targeted, have been tested against and in combination with this standard. Many combination therapy regimens showed encouraging results in Phase II settings, which led to > 12 randomized Phase III trials in the last decade. Some trials showed improved response rates or progression-free survival, but there was no clear improvement in survival. Among these combinations, the combination of gemcitabine plus platinum agents showed improved progression-free survival or time-to-tumor progression, but failed to demonstrate a survival advantage over gemcitabine. This combination has regained attention after a recent pooled analysis and a meta-analysis suggested a survival benefit of gemcitabine-platinum doublets when compared with single agent gemcitabine. There are preclinical data showing synergism between gemcitabine and platinum agents. Hence, this review covers the role of platinum doublets in the treatment of metastatic pancreatic cancer.Keywords
This publication has 28 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Randomized Phase III Study of Exatecan and Gemcitabine Compared With Gemcitabine Alone in Untreated Advanced Pancreatic CancerJournal of Clinical Oncology, 2006
- Gemcitabine and Oxaliplatin in Patients With Pancreatic AdenocarcinomaPancreas, 2006
- Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology GroupAnnals of Oncology, 2005
- A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trialEuropean Journal of Cancer, 2005
- Gemcitabine Combined With Oxaliplatin in Advanced Pancreatic Adenocarcinoma: Final Results of a GERCOR Multicenter Phase II StudyJournal of Clinical Oncology, 2002
- Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinomaCancer, 2002
- Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancerInternational Journal of Cancer, 2000
- Activity of cisplatin in adenocarcinoma of the pancreasEuropean Journal of Cancer, 1993
- The integration of chemotherapy into a combined modality approach for cancer treatment: VI. Pancreatic adenocarcinomaCancer Treatment Reviews, 1975